Amlodipine

證據等級: L5

預測適應症: 10 個

Amlodipine: From Hypertension to Brain Stem Infarction

One-Sentence Summary

Amlodipine is a dihydropyridine calcium channel blocker (CCB) widely used in the treatment of hypertension and angina pectoris. The TxGNN model predicts it may be effective for Brain Stem Infarction, with a prediction score of 99.94%. Currently, no clinical trials or published literature specifically supporting this indication have been identified, placing this at Evidence Level L5.

Quick Overview

Item	Content
Original Indication	Hypertension / Stable Angina Pectoris
Predicted New Indication	Brain Stem Infarction
TxGNN Prediction Score	99.94%
Evidence Level	L5
South Africa Market Status	No active SAHPRA registration found in current dataset
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action (MOA) data for amlodipine is not available in this evidence pack. Based on well-established pharmacological knowledge, amlodipine is a dihydropyridine L-type calcium channel blocker that causes selective peripheral arterial vasodilation, reduces systemic vascular resistance, and lowers blood pressure without reflex tachycardia. Its efficacy in hypertension and stable angina pectoris is well-established, and it is included on the WHO Model List of Essential Medicines.

The TxGNN prediction linking amlodipine to brain stem infarction is mechanistically plausible via two indirect pathways. First, persistent hypertension is the single most important modifiable risk factor for ischaemic stroke — including posterior circulation and brain stem infarction — and sustained blood pressure reduction with amlodipine may therefore lower the incidence and severity of such events. Second, calcium channel blockade has been proposed to attenuate the ischaemic calcium overload that triggers neuronal death following arterial occlusion, potentially offering a degree of neuroprotection that goes beyond blood pressure reduction alone.

It must be emphasised, however, that these mechanistic links are indirect inferences. No clinical studies directly targeting brain stem infarction with amlodipine have been identified to date, and the prediction remains at the model-generation stage only. Clinical validation is required before any recommendation can be made.

Clinical Trial Evidence

Currently no related clinical trials registered for Brain Stem Infarction.

Literature Evidence

Currently no related literature available for Brain Stem Infarction.

South Africa Market Information

No SAHPRA registrations are currently recorded in this evidence pack for Amlodipine.

Data Note: Amlodipine is a widely available generic medicine registered in many countries worldwide. The absence of records in this dataset may reflect a data retrieval limitation rather than true non-registration in South Africa. Healthcare professionals are advised to verify current registration status directly via the SAHPRA online database at www.sahpra.org.za. Amlodipine 5 mg and 10 mg tablets may also appear on the South African Essential Medicines List (EML) — please confirm against the current EML edition. Adverse drug reactions should be reported to SAHPRA via the MedSafety reporting system.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Conclusion and Next Steps

Decision: Hold

Rationale: Although the TxGNN model assigns a high prediction score (99.94%) to the amlodipine–brain stem infarction pairing, this prediction currently rests on indirect mechanistic inference alone, with no supporting clinical trials, observational studies, or published literature specific to this indication (Evidence Level L5). The prediction cannot be actioned until foundational evidence is obtained.

To proceed, the following is needed:

Retrieve amlodipine MOA data from DrugBank (DB00381) to formalise and strengthen the mechanistic rationale
Conduct a targeted literature search for calcium channel blockers in brain stem or posterior circulation ischaemia specifically
Obtain and review the SAHPRA-approved Professional Information (PI) for amlodipine to complete the safety assessment (contraindications, key warnings, and clinically significant drug interactions)
Confirm current SAHPRA registration status and available formulations, including whether amlodipine features on the current South African Essential Medicines List (EML)
Examine subgroup data from large-scale completed hypertension trials in which amlodipine was a study arm (e.g., ALLHAT, VALUE, ACCOMPLISH) for any posterior circulation or brain stem infarction outcome data that may upgrade the evidence level above L5

⚕️ Disclaimer: This report is generated for research reference purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before therapeutic application. This document is intended for use by qualified South African healthcare professionals only.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.